AOD9604, a synthetic fragment of hGH consisting of the amino acid residues 177–191 with the addition of a tyrosine residue to the N-terminus was prepared with solid-phase synthesis procedure and purified with reverse-phase HPLC methodology in our laboratories (13). The structure of the peptide analog was verified with mass spectrometry and amino acid analysis. The hGH was a gift of Professor Michael Waters (University of Queensland, Brisbane, Australia). BRL37344 (β3-AR agonist) was a gift from Dr. Jon Arch (SmithKline Beecham, Harlow, UK).
The increase in GH secretion due to IPAMORELIN (and other GHRP) leads to an increase in IGF-1 (thought to be the anabolic mechanism of GH). As we get older GH and subsequently IGF-1 decrease substantially. This decline is thought to be one of the major causes of the ageing process. By increasing these levels again there is increased collagen synthesis, promotion of lean muscle mass, bone strength, improved healing capability, improved sleep cycle, increased energy, repair and regeneration of internal organs, strengthening of joints/cartilage/connective tissue, and anti ageing effects on the skin.
Meanwhile, more Phase II clinical studies are planned for the next 12 months including a study examining the efficacy of oral administration, which has been shown to be effective in laboratory animals. This will be followed by a weight loss study. Confirmation of the age-effect will also be sought. Metabolic aims to start a two-year Phase III studies program in 2003, which would not place final FDA approval before 2005.
Five patients in the study reported a serious AE; three in the AOD9604 20 mg group (basal cell carcinoma, moderate lipoma and squamous cell carcinoma), one in the 5 mg group (breast cancer) and one in the 10 mg group (malignant melanoma). According to the investigator, none of the SAEs reported were considered to be possibly, probably or definitely related to study medication (see discussion).
also using a dose of 400mcg for the IPAM is really a waste of your peptides as anything above saturation dose will give diminished returns, saturation dose(1mcg per kg) is a dose that will give maximum return, if you double the saturation dose then you will not get double the GH pulse in fact no where near that, then the more you use the less added benefit you will get.
Perhaps. As Dr Larkins weighs in: "It's a different kind of chemical and physiological manipulation that goes way beyond what I'd call conventional hormone therapy. It's the next stage of technology that's come along to try and help people enjoy quality of life." A stage with an effect apparently significant enough to risk a professional athletic career for.
Ipamorelin is a man-made peptide that is part of the growth hormone family. Rated as one of the safest in the peptide industry, it has strong growth hormone releasing properties. From this, it is a huge winner with athletes and bodybuilders. This is because it builds muscle and keeps weight down quickly. It works by sending signals to the pituitary gland at the base of the brain and adjusts and controls various body functions through the endocrine system. It binds certain receptors inside cells. This allows cells to respond and change, encouraging growth and regulation of hormones. Ipamorelin can help with:
In plasma, different isoforms and fragments of hGH were found . Research on specific domains and fractions of the protein revealed that they can be assigned to different actions of the protein: In vitro and in vivo experiments have shown that several fragments of the amino terminal region of hGH, namely 1-15, 1-42, 6-13, and 32-46, exhibit an insulin-potentiating action [14-16]. The region hGH 108-129 was found to evoke high mitogenic responses , while the carboxy terminus hGH177-191 seemed to be a lipid mobilizing domain, inhibiting the acetyl-CoA carboxylase activity in adipocytes and hepatocytes .
CJC 1295 is a fast working growth hormone releasing hormones devised to reduce the effects of ageing. It works by stimulating the body’s natural growth hormone production and the release of IGF-1. The advantages of the CJC peptide is it helps increases bone density and collagen, as well as boosting the immune system. It will also produce new muscle cells which will be leaner and increases weight loss. The CJC 1295 results are part of years of scientific studies. It primarily increases the production of proteins, which leads to stable bodily functions related to the glands in the body or the endocrine system.
Over the last 40 years a lot of research has been done on various peptides developing new peptide sequences to produce new peptides with fewer side effects and new beneficial effects. For example fragments of the growth hormone peptide have been developed such as AOD 9604 which possess all the fat burning properties of growth hormone without any of its adverse effects on blood sugar or growth.
Some of these chains are pivotal in stimulating the release of natural human growth hormone (HGH), an element within the body that naturally declines significantly as we age. The hormone acts to repair and maintain our body, and as the levels of HGH reduce in our body the ability to fight aging, maintain vitality and manage our overall health declines.
Growth Hormone (GH) exhibits its muscle building effects mainly after its conversion to IGF-1 (Insulin-Like-Growth Factor). This makes IGF-1 an ideal choice of peptides for muscle building, especially since the IGF-1 LR3 version has an extended half-life which allows it to remain active in the muscles for many hours to complete its muscle building stimulatory effects. Likewise, if injected after a workout, the IGF-1 variant Mechano Growth Factor (also known as MGF or IGF-1e) is known to multiply muscle cells and contribute to muscle development. Furthermore, since IGF-1 is a by-product of GH, any peptide which increases levels of GH in the body such as a GHRP product or CJC-1295 product will obviously lead to increased lean muscle mass.
Smeath says he turns patients away on a weekly basis. "[Particularly] if a patient comes and asks me for a specific peptide and it's not right for them. It's the same as if an anti-biotic was unsuitable for a patient, we don't just prescribe it." He says a lot of people prefer face-to-face contact with the prescribing doctor, but if geography restricts them, phone and Skype sessions also take place.
We enrolled 15 obese individuals (mean BMI 45±5.4 kg/m2) undergoing gastric bypass surgery. Before and 6 months after surgery, subjects were admitted to the clinical research center and administered a large‐volume intravenous saline challenge. Echocardiography and serial blood sampling were performed. From the pre‐operative visit to 6 months after surgery, subjects had a mean BMI decrease of 27%. At the 6‐month visit, N‐terminal pro‐atrial NP (Nt‐proANP) levels were 40% higher before, during, and after the saline infusion, compared with levels measured at the same time points during the pre‐operative visit (P<0.001). The rise in Nt‐pro‐ANP induced by the saline infusion (≈50%) was similar both before and after surgery (saline, P<0.001; interaction, P=0.2). Similar results were obtained for BNP and Nt‐proBNP; resting concentrations increased by 50% and 31%, respectively, after gastric bypass surgery. The increase in NP concentrations after surgery was accompanied by significant decreases in mean arterial pressure (P=0.004) and heart rate (P<0.001), and an increase in mitral annular diastolic velocity (P=0.02).
In June 2010, the National Drugs and Poisons Schedule Committee (NDPSC) considered the scheduling of paracetamol in combination with ibuprofen. Paracetamol preparations containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine, effervescent agents or guaiphenesin) in packs of 25 or less were exempt from scheduling. However, when these preparations were combined with another therapeutically active ingredient they became Schedule 2. The NDPSC considered that the Schedule 2 entry remained appropriate, but noted the possibility that more robust evidence of additional risk could come to light through any application for product approval with the Therapeutic Goods Administration. The delegate confirmed the NDPSC's decision and the reasons for the decision in August 2010.
CJC 1295 has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC 1295 shown potential to increase growth hormone and IGF-I secretion and effects, but it has been able to do so in very large amounts. CJC 1295 Stimulates Growth Hormone Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to fat loss, and increased protein synthesis thereby promoting growth.
In lean animals, neither AOD9604 nor hGH had any effect on epididymal white adipose tissue mass or expression ofβ 3-AR RNA, indicating that in lean animals, this fat tissue is not a major target for these drugs in this study. In contrast, the mass of BAT in lean animals was reduced by both hGH and AOD9604, and β3-AR RNA expression was increased by both these compounds. This could possibly suggest that the increased expression of β3-ARs in brown adipocytes sensitizes catecholamines to dissipate heat.
The ACMS recommended listing Growth Hormone Releasing Hormones (GHRHs), Growth Hormone Secretagogues (GHSs), Growth Hormone Releasing Peptides (GHRPs) as well as new individual substance entries for CJC-1295, ipamorelin, pralmorelin (Growth Hormone Releasing Peptide-2), Growth Hormone Releasing Peptide-6, hexarelin and AOD-9604 in Appendix D, Item 5.
A total of 97 AEs were reported by 17/17 subjects during this study. Most of them were of mild or moderate in intensity, with the exception of two SAEs, one of which (diarrhoea) was deemed “possibly related” to study treatment (54 mg AOD9604) and one (bronchial pneumonia) deemed to be “unrelated” to the study treatment (54 mg AOD9604). The most common adverse event reported was mild or moderate headache followed by events related to the digestive system, specifically diarrhea, flatulence, increased appetite and nausea. There was no observable trend between the AOD9604 groups or the placebo with respect to the incidence. The only event deemed definitely related to the treatment was taste perversion occurring 10 minutes following dose administration of the placebo.
Django Nathan, a medical doctor with a degree in molecular biology and genetics, takes peptides because of his busy lifestyle: "Quite a few doctors I know are using them because they have so many beneficial effects and so few side effects. We're not elite athletes – we live rushed lives that can involve 70 hour weeks so staying fit and getting good sleep is essential – and peptides aid that."